On 28 October 2010, India’s Central Drugs Standard Control Organization (CDSCO) released new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.
India regulatory authority to adopt CTD format for NDAs
Home/Guidelines
|
Posted 11/02/2011
0
Post your comment
The CTD has already been developed for Japan, the EU and the US through the International Conference on Harmonisation (ICH) process.
Up until now, applicants in India have used many different approaches in organising the information for NDAs and the differences in organisation of data in each application has made reviewing difficult and has often resulted in the omission of critical data or analyses, in turn leading to unnecessary delays in approval.
By adopting the CTD format the CDSCO hopes to improve approval times for the importation, manufacture and marketing of new drugs. In addition, this should also simplify the exchange of regulatory information between India and other regulatory authorities.
The guidance document is available for comment for 60 days on the website of the CDSCO.
Source: CDSCO
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Related content
FDA issues guidance on AI use in drug and biologicals regulatory decision making
Home/Guidelines Posted 25/02/2025
Regulatory update for post-registration of biological products in Brazil
Home/Guidelines Posted 29/10/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment